A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes

Inclusion Criteria: * Have Body Mass Index (BMI) at screening of the following: * 30 kilogram per square meter (kg/m2) OR * 27 kg/m2 with at least one of the following weight-related health conditions at screening: * high blood pressure * dyslipidemia * obstructive sleep apnea, or * heart disease * Have a stable body weight (\<5% body weight change) for 90 days prior to screening. * Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cry…